Safety of a universal, virus-inactivated and prion-depleted, pharmaceutical-quality plasma: A randomized, double-blind, clinical trial in healthy volunteers

Transfusion

Volumn 51, Issue 6, 2011, Pages 1228-1240

  Jilma Stohlawetz, Petra ^a,b   Kursten, Friedrich W ^a,b   Walasek, Claudia ^a,b   Horvath, Michaela ^a,b   Leitner, Gerda ^a,b   List, Jana ^a,b   Quehenberger, Peter ^a,b   Schwameis, Michael ^a,b   Bartko, Johann ^a,b   Jilma, Bernd ^a,b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Research and Development Department   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

BILIRUBIN; HAPTOGLOBIN; HEMOGLOBIN;

ADULT; ARTICLE; BLOOD GROUP A; BLOOD GROUP AB; BLOOD GROUP ABO SYSTEM; BLOOD GROUP B; BLOOD SAFETY; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; COOMBS TEST; DOUBLE BLIND PROCEDURE; DYSPNEA; FATIGUE; FEMALE; HEADACHE; HUMAN; HYPOTENSION; MALE; MIGRAINE; NORMAL HUMAN; OUTCOME ASSESSMENT; PARESTHESIA; PHASE 1 CLINICAL TRIAL; PLASMA; PLASMA TRANSFUSION; PLASMAPHERESIS; RANDOMIZED CONTROLLED TRIAL; URTICARIA;

ABO BLOOD-GROUP SYSTEM; BLOOD COMPONENT TRANSFUSION; DOUBLE-BLIND METHOD; HUMANS; PLASMA; PLASMAPHERESIS; VIRUS INACTIVATION;

EID: 79958803279     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2010.03005.x     Document Type: Article

References (27)

1. McManigal S, Sims KL,. Intravascular hemolysis secondary to ABO incompatible platelet products. An underrecognized transfusion reaction. Am J Clin Pathol 1999; 111: 202-6. (Pubitemid 29054947)
2. Duguid JK, Minards J, Bolton-Maggs PH,. Lesson of the week: incompatible plasma transfusions and haemolysis in children. BMJ 1999; 318: 176-7. (Pubitemid 29192613)
3. Flesland O, Seghatchian J, Solheim BG,. The Norwegian Plasma Fractionation Project-a 12 year clinical and economic success story. Transfus Apher Sci 2003; 28: 93-100. (Pubitemid 36298596)
4. Race RR, Sanger R,. The ABO blood groups. In:, Race RR, Sanger R, editors. Blood groups in man. Oxford: Blackwell Scientific Publications; 1975. p. 10ff.
5. Anonymous. 2010. Blood types in the U.S. [cited 2010 Dec 23]. Available from: URL
6. Tollofsrud S, Noddeland H, Svennevig JL, Bentsen G, Mollnes TE, Solheim BG,. Universal fresh frozen plasma (Uniplas): a safe product in open-heart surgery. Intensive Care Med 2003; 29: 1736-43. (Pubitemid 37373818)
7. Solheim BG, Chetty R, Flesland O,. Indications for use and cost-effectiveness of pathogen-reduced ABO-universal plasma. Curr Opin Hematol 2008; 15: 612-7.
8. Heger A, Kannicht C, Romisch J, Svae TE,. Normal levels of ADAMTS13 and factor H are present in the pharmaceutically licensed plasma for transfusion (Octaplas) and in the universally applicable plasma (Uniplas) in development. Vox Sang 2007; 92: 206-12. (Pubitemid 46365025)
9. Heger A, Romisch J, Svae TE,. A biochemical comparison of a pharmaceutically licensed coagulation active plasma (Octaplas) with a universally applicable development product (Uniplas) and single-donor FFPs subjected to methylene-blue dye and white-light treatment. Transfus Apher Sci 2006; 35: 223-33. (Pubitemid 44839266)
10. Solheim BG,. Universal pathogen-reduced plasma in elective open-heart surgery and liver resection. Clin Med Res 2006; 4: 209-17. (Pubitemid 44496014)
11. Heger A, Svae TE, Neisser-Svae A, Jordan S, Behizad M, Romisch J,. Biochemical quality of the pharmaceutically licensed plasma OctaplasLG after implementation of a novel prion protein (PrPSc) removal technology and reduction of the solvent/detergent (S/D) process time. Vox Sang 2009; 97: 219-25.
12. Neisser-Svae A, Bailey A, Gregori L, Heger A, Jordan S, Behizad M, Reichl H, Romisch J, Svae TE,. Prion removal effect of a specific affinity ligand introduced into the manufacturing process of the pharmaceutical quality solvent/detergent (S/D)-treated plasma OctaplasLG. Vox Sang 2009; 97: 226-33.
13. Solheim BG, Granov DA, Juravlev VA, Krawczyk M, Kubishkin VA, Patutko UI, Raab R,. Universal fresh-frozen plasma (Uniplas): an exploratory study in adult patients undergoing elective liver resection. Vox Sang 2005; 89: 19-26. (Pubitemid 40839546)
14. Anonymous. 2010. Summary of product characteristics, Octaplas. [cited 2010 Dec 23]. Available from: URL
15. CHMP. 2008. Guideline on the investigation of bioequivalence CPMP/EWP/QWP/1401/98 Rev. 1. [cited 2010 Dec 23]. Available from: URL
16. FDA. 2001. Guidance for industry. Statistical approaches to establishing bioequivalence. [cited 2010 Dec 23]. Available from: URL
17. Mair B, Benson K,. Evaluation of changes in hemoglobin levels associated with ABO-incompatible plasma in apheresis platelets. Transfusion 1998; 38: 51-5. (Pubitemid 28090940)
18. Shanwell A, Ringden O, Wiechel B, Rumin S, Akerblom O,. A study of the effect of ABO incompatible plasma in platelet concentrates transfused to bone marrow transplant recipients. Vox Sang 1991; 60: 23-7.
19. Krombach J, Kampe S, Gathof BS, Diefenbach C, Kasper SM,. Human error: the persisting risk of blood transfusion: a report of five cases. Anesth Analg 2002; 94: 154-6. Table of contents. (Pubitemid 34038737)
20. AuBuchon JP, Kruskall MS,. Transfusion safety: realigning efforts with risks. Transfusion 1997; 37: 1211-6.
21. Baele PL, De Bruyere M, Deneys V, Dupont E, Flament J, Lambermont M, Latinne D, Steensens L, van Camp B, Waterloos H,. Bedside transfusion errors. A prospective survey by the Belgium SAnGUIS Group. Vox Sang 1994; 66: 117-21. (Pubitemid 24047345)
22. Busch MP, Kleinman SH, Jackson B, Stramer SL, Hewlett I, Preston S,. Committee report. Nucleic acid amplification testing of blood donors for transfusion-transmitted infectious diseases: report of the Interorganizational Task Force on Nucleic Acid Amplification Testing of Blood Donors. Transfusion 2000; 40: 143-59.
23. Hourfar MK, Jork C, Schottstedt V, Weber-Schehl M, Brixner V, Busch MP, Geusendam G, Gubbe K, Mahnhardt C, Mayr-Wohlfart U, Pichl L, Roth WK, Schmidt M, Seifried E, Wright DJ,. Experience of German Red Cross blood donor services with nucleic acid testing: results of screening more than 30 million blood donations for human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus. Transfusion 2008; 48: 1558-66.
24. Linden JV, Wagner K, Voytovich AE, Sheehan J,. Transfusion errors in New York State: an analysis of 10 years' experience. Transfusion 2000; 40: 1207-13.
25. Nubling CM, Unkelbach U, Chudy M, Seitz R,. Effect of viral nucleic acid testing on contamination frequency of manufacturing plasma pools. Transfusion 2008; 48: 822-6. (Pubitemid 351614895)
26. Kruskall MS, AuBuchon JP,. Making Landsteiner's discovery superfluous: safety and economic implications of a universal group O red blood cell supply. Transfus Sci 1997; 18: 613-20.
27. Stainsby D,. Haemovigilance in the United Kingdom and Europe. Hematol J 2004;(5 Suppl 3): S175-8. (Pubitemid 39077299)